3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
3
Gynecologic
2
Plasma cell
1
Lymphoid
1
Gastrointestinal
1
Breast
1
Conditions
Multiple Myeloma
940
Lymphoma
113
Recurrence
94
Neoplasms, Plasma Cell
92
Lymphoma, Non-Hodgkin
69
Immunoglobulin Light-chain Amyloidosis
60
Hematologic Neoplasms
60
Neoplasms
54
Smoldering Multiple Myeloma
52
Leukemia, Myeloid, Acute
51
Leukemia
51
Myelodysplastic Syndromes
47
Leukemia, Lymphocytic, Chronic, B-Cell
45
Precursor Cell Lymphoblastic Leukemia-Lymphoma
38
Hodgkin Disease
38
Leukemia, Plasma Cell
27
Myeloproliferative Disorders
24
Breast Neoplasms
24
Monoclonal Gammopathy of Undetermined Significance
23
Lymphoma, Large B-Cell, Diffuse
23
Lymphoma, Mantle-Cell
22
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
22
Amyloidosis
22
Primary Myelofibrosis
21
Lymphoma, Follicular
21
Waldenstrom Macroglobulinemia
20
Ovarian Neoplasms
20
Lymphoma, B-Cell, Marginal Zone
17
Lymphoma, B-Cell
17
Colorectal Neoplasms
17
Interventions
liposomal doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
AIDS-related Kaposi sarcoma
×
Plasma cell
×
1 year
×
Clear all
NCT05567601
2025-06-05
Doxil/Caelyx BE Study
Baxter Healthcare Corporation
Phase 1
Completed
36 enrolled